ClinicalTrials.gg
CompletedNCT06318676Updated Jun 4, 2025

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

A Phase 1 interventional study of Mezigdomide in Renal Impairment, sponsored by Celgene. Completed at 3 sites in United States. Open to participants aged 18 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Primary conditionKidney Failure, ChronicRegistry: Renal InsufficiencyReclassifiedWhy we changed it
Registry
Renal Insufficiency — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's title name Kidney Failure, Chronic, a narrower term within Renal Insufficiency.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
416th of 638
26 · median 48
Started
2024
with 23 others
Phase 1
89 of 765
8 open now
Registered
717th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 416th largest by enrollment of the 638 interventional ones that give a count, is one of 24 that started in 2024, is one of 89 in phase 1, and was the 717th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Chronic Kidney Disease
  • End Stage Renal Disease
  • Dialysis
  • Hemodialysis
  • Mezigdomide
  • Pharmacokinetics
  • Healthy
04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 26 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a (BMI) of ≥ 18.0 kg/m2 to ≤ 40.0 kg/m2 inclusive at screening.
  • Participants must have a body weight ≥ 50 kg at screening.
  • Participants must be afebrile (febrile is defined as ≥ 38°C or 100.4°F) at screening, check in, and predose.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any history of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide.
  • Participants must not have any history of of any type other than in situ cervical cancer or surgically excised non-melanomatous skin cancers.
  • Participants with an inability to tolerate oral medication.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Group A: Participants with severe renal impairment

    Drug: Mezigdomide

  • Experimental
    Group B: Participants with End Stage Renal Disease

    Drug: Mezigdomide

  • Experimental
    Group C: Participants with normal renal function

    Drug: Mezigdomide

Interventions

  • Specified dose on specified days

    Also known as: BMS-986348, CC-92480

07

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 24 days

  2. Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 24 days

  3. Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to 24 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 54 days

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 54 days

  3. Number of participants with physical examination findings

    Time frame: Up to 24 days

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 24 days

  5. Number of participants with 12-lead electrocardiogram (ECG) findings

    Time frame: Up to 24 days

  6. Maximum observed concentration (Cmax)

    Time frame: Up to 24 days

  7. Time of maximum observed concentration (Tmax)

    Time frame: Up to 24 days

  8. Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 24 days

08

Study locations

3 sites
  • PANAX
    Miami Lakes, Florida 33014, United States
  • Omega Research Group - Orlando
    Orlando, Florida 32806, United States
  • Orlando Clinical Research Center OCRC
    Orlando, Florida 32809, United States
09

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Nov 2024, 7 months.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 7 months is close to that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
Mar 21, 2024
Primary completionActual
Nov 15, 2024
CompletionActual
Nov 15, 2024
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06318676
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Mar 21, 2024
Primary completion
Nov 15, 2024
Completion
Nov 15, 2024
Last update
Jun 4, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion